Rational design of peptide vaccines for autoimmune disease: Harnessing molecular recognition to fix a broken network

Expert Review of Vaccines

Volumn 2, Issue 1, 2003, Pages 61-73

  Weathington, Nathaniel M ^a   Blalock, J Edwin ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anti idiotypic antibody; Complementary peptides; Giullan Barre's syndrome; Immune network; Multiple sclerosis; Myasthenia gravis; Sjogren's syndrome; Systemic lupus erythematosus; T cell receptor

Indexed keywords

ANTICONVULSIVE AGENT; AZATHIOPRINE; BACLOFEN; BETA INTERFERON; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EDROPHONIUM; EPITOPE; GLATIRAMER; IMMUNOGLOBULIN; LYMPHOCYTE ANTIGEN RECEPTOR; MITOXANTRONE; NEOSTIGMINE; PEPTIDE; T LYMPHOCYTE RECEPTOR PEPTIDE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ALGORITHM; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DEPRESSION; DISEASE EXACERBATION; DRUG DESIGN; GUILLAIN BARRE SYNDROME; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLUENZA; MOLECULAR RECOGNITION; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PAIN; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SPASTICITY; VACCINATION;

ALGORITHMS; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; EPITOPES; GUILLAIN-BARRE SYNDROME; HUMANS; HYDROPHOBICITY; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ACTIVE; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PROTEIN CONFORMATION; PROTEIN FOLDING; RATS; RECEPTORS, ANTIGEN, T-CELL; VACCINES, SUBUNIT;

EID: 0037992519     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.1.61     Document Type: Review

References (65)

1. Hauser SL, Goodkin DE. Multiple Sclerosis and other demyelinating diseases. In: Harrison's Principles of Internal Medicine. McGraw Hill, OH, USA (2001).
2. Drachman DB. Myasthenia Gravis and other diseases of the neuromuscular junction. In: Harrison's Principles of Internal Medicine. McGraw Hill, OH, USA (2001).
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Medical Progress: Multiple Sclerosis N. Engl. J. Med. 343, 938-952 (2000).
4. Vandenbark AA, Chou YK, Whitham R et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. 10, 1109-1115 (1996).
5. Zang Y, Hong J, Rivera V, Killian J, Zhang J. Preferential recognition of hypervariable region sequence by and-idiotypic T-cells induced by T-cell vaccination in patients with multiple sclerosis. J. Immunol. 164, 4011-4017 (2000).
6. Bell RB, Lindsey JW, Sobel RA, Hodgkinson S, Steinman L. Diverse T-cell receptor V beta gene usage in the central nervous system in experimental allergic encephalomyelitis. J. Immunol. 150, 4085-4092 (1993).
7. Tejeda-Simon MV, Ying C, Yang D et al. Aberrant T-cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int. Immunol. 12, 1642-1650 (2000).
8. McCluskey J, Farris AD, Keech CL et al. Determinant spreading: lessons from animal models and human disease. Immunol. Rev. 164, 209-229 (1998).
9. Vanderlugt CL, Miller SD. Epitope spreading in immune mediated diseases: Implications for immunotherapy. Nat. Rev. Immunol. 2, 85-95 (2002).
10. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341, 541-544, (1989). Among the first demonstrations that immunization with antigen receptor peptides can protect against autoimmune disease by inducing anti-Id responses.
11. Blalock JE. Genetic origins of protein shape and interaction rules. Nat. Med. 1, 876-878 (1995). Theoretical discussion of hydropathy driven protein ineractions.
12. Kamtekar S, Schiffer JM, Xiong H, Babik JM, Hecht MH. Protein design by binary patterning of polar and nonpolar amino acids. Science 262, 1680-1685 (1993)
13. Riddle DS, Santiago JV, Bray-Hall ST, Doshi N, Grantcharova VP, Yi Q, Baker D. Functional rapidly folding proteins from simplified amino acid sequences. Nat. Struct. Biol. 4, 805-809 (1997).
14. Weigent DA, Clarke BL, Blalock JE. Peptide design using a genetically patterned binary code: Growth hormone releasing hormone as a model. Immunomethods 5, 91-97 (1992).
15. Clarke BL, Blalock JE. Steroidogenic activity of a peptide specified by the reversed sequence of corticotropin mRNA. Proc. Natl Acad. Sci. USA 87, 9708-9711 (1990).
16. Akanuma S, Kigawa T, Yokoyama S. Combinatorial mutagenesis to restrict amino acid usage in an enzyme to a reduced set. Proc. Natl Acad. Sci. USA. 99, 13549-13553 (2002).
17. Blalock JE, Smith EM. Hydropathic anticomplementarity of amino acids based on the genetic code. Biochem. Biophys. Res. Comm. 121, 203-207 (1984).
18. Baranyi L, Campbell W, Ohshima K, Fujimoto S, Boros M, Okada H. The antisense homology box: A new motif within proteins that encodes biologically active peptides. Nat. Med. 1, 894-901. (1995). Reviews reports on the role of hydropathy in ligand-receptor interactions
19. McGuigan JE. Antibodies to complementary petpides as probes for receptors. ImmunoMethods - Complementary Peptides: Applications in Immunology and as Antibody Mimetics 5, 158-166 (1994).
20. Eberle AN, Huber M. Antisense peptides of ACTH and MSH: tools for receptor isolation? In: Antisense Nucleic Acids and Proteins, Fundamentals and Applications. Mol NMJ, Krol RV-D Marcel Dekker Inc., New York, NY, USA (1991).
21. Guillemette G, Boutlay G, Gagnon S, Bosse R, Escher E. The peptide encoded by angiotensin II complementary RNA does not interfere with angiotensin II action. Biochem. J. 269, 309 (1989).
22. De Gasparo MS, Whitebread S, Einsle K, Huesser C. Are the antibodies to a peptide complementary to angiotensin II useful to isolate the angiotensin II receptor? Biochem. J. 261, 310-311 (1989).
23. Jurzak M, Pavo I and Fharenholz F. Lack of interaction of vasopressin with its antisense peptides: a functional and immunological study. J. Chem Soc. 1, 1407-1415 (1993).
24. Rasmussen UB, Hesch HD. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view. Biochem. Biophys. Res. Comm. 149, 930-938 (1987).
25. Martins VR, Graner E, Garcia-Abreu J et al. Complementary hydropathy identifies a cellular prion protein receptor. Nat. Med. 3, 1376-1382 (1997).
26. Ruiz-Opazo N, Hirayama K, Akimoto K, Herrera VLM. Molecular characterization of a dual endothelin-1/angiotensin II receptor. Mol. Med. 4, 96-108 (1998).
27. Ruiz-Opazo N, Akimoto K, Herrera VLM. Identification of a novel dual angiotensin/vasopressin receptor: Direct evidence for the molecular recognition code hypothesis. Nat. Med. 1, 1074-1081 (1995).
28. Goicoechea S, Pallero MA, Eggleton P, Michalak M, Murphy-Ullrich JE. The antiadhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin. J. Biol. Chem. 277, 37219-37228 (2002).
29. Crawford SE, Stellmach V, Murphy-Ullrich JE et al. Thrombospondin-1 is a major activator of TGF-b1 in vivo. Cell 93, 1159-1170 (1998).
30. Fassina G, Consonni R, Zetta L and Cassani G. Design of hydropathically complementary peptides for Big Endothelin affinity purification. Int. J. Peptide Protein Res. 39, 540-548 (1992).
31. Gho YS, Chae C-B. Anti-angiogenin activity of the peptides complementary to the receptor-binding site of angiogenin. J. Biol. Chem. 272, 24294-24299 (1997).
32. Villain M, Jackson PL, Manion MK et al. De novo design of peptides targeted to the EF hands of calmodulin. J. Biol. Chem. 274, 2676-2685 (2000). Demonstrates the use of hydropathy patterning to design peptides that will interact with a selected site.
33. Smith LR, Bost KL, Blalock JE. Generation of idiorypic and anti-idiotypic antibodies by immunization with peptides encoded by complementary RNAs: A possible molecular basis for the network theory. J. Immunol. 138, 7-9 (1987). First demonstration of the production of an anti-Id Ab to a complementary peptide rather than an Id Ab.
34. Bost KL, Blalock JE. Production of antiidiotypic antibodies by immunization with a pair of complementary peptides. J. Mol. Recogn. 1, 179-183 (1987).
35. Jerne NK. Towards a network theory of the immune system. Annales d'Immunologie (Institute Pasteur) 125 C, 373-389 (1974)
36. Déry O, Frobert Y, Zerari F, Conrath M, Grassi J, Couraud J-Y. A monoclonal antibody directed at a substance P binding site in mammalian tissues: production and biochemical characterization. Neuropeptides 26(Suppl. 1), 2 (1994).
37. Sagot M-A, Wijkhuisen S, Creminon C et al. A monoclonal antibody directed against the neurokinin-1 receptor contains a peptide sequence with similar hydropathy and functional properties to substance P, the natural ligand for the receptor. Mol. Immunol. 37, 423-433 (2000). Shows that the antigen-binding sites of many anti-Id Ab carry an internal image that has similar hydropathic pattern to the original antigen, displaying that hydropathy drives antigen-antibody interactions.
38. Selo I, Creminon C, Grassi J, Couraud J-Y. Anti-allergen antibodies can be neutralized by antibodies obtained against a peptide complementary to the allergen: towards a new peptide therapy for allergy. Immunol. Lett. 80, 133-138 (2002).
39. Reitan SK, Hannestad K. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc. Natl Acad. Sci. USA 99, 7588-7593 (2002).
40. Routsias JG, Touloupi E, Dotsika E et al. Unmasking the antiLa/SSB response in sera from patients with Sjogren's Syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants. Mol. Med. 8, 293-305 (2002). Shows that circulating immune complexes of Id/anti-Id antibodies are present in the serum of humans with autoimmune diseases and describes the use of ARM peptides in a novel method for detection of autoreactive Ab that may be undetectable due to Id/anti-Id networks in these patients.
41. Araga S, LeBoeuf RD, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proc. Natl Acad. Sci. USA 90, 8747-8751 (1993). First use of an ARM peptide to protect against an autoimmune disease - shows binding of pathogenic Ab and clinical protection against EAMG.
42. Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. J. Immunol. 157, 386-392 (1996).
43. Araga S, Xu LK, Nakashima K, Villain M, Blalock JE. A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T-cell help. FASEB J. 14, 185-196 (2000). Uses an ARM peptide to vaccinate against T-cell help in EAMG.
44. Yeh TM, Krolick KA. T-cells reactive with a small synthetic peptide acetylcholine receptor can provide help for a clonotypically heterogeneous antibody response and subsequently inpaired muscle function. J. Immunol. 144, 1654-1660 (1990).
45. Xu L, Villain M, Galin FS, Araga S, Blalock JE. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T-cells. Cell Immunol. 208, 107-114 (2000).
46. Zhou S-R, Whitaker JN. Specific modulation of T-cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J. Immunol. 150, 1629-1642 (1993).
47. Zhou S-R, Whitaker JN. Active immunization with complementary peptide PBM 9-I: Preliminary evidence that it modulates experimental allergic encephalomyelitis in PL/J mice and Lewis rats. J. Neurosci. Res. 45, 439-446 (1996). Shows that immunization with an ARM in EAE is effective against against a T-cell disease, that it protects two different species and that anti-Id Ab anergizes autoreactive T-cell clones.
48. Brostoff S, Burnett P, Lampert P, Eylar E. Isolation and characterization of a protein from sciatic nerve myelin responsible for experimental autoimmune neuritis. Nat. New. Biol. 235, 210 (1972).
49. Araga S, Kishimoto M, Doi S, Nakashima K. A complementary peptide vaccine that induces T-cell anergy and prevents experimental autoimmune neuritis in Lewis rats. J. Immunol. 163, 476-482 (1999). Uses an ARM vaccine to protect against EAN.
50. Genain CP, Abel K, Belmar N et al. Late Complications of Immune Deviation Therapy in a Nonhuman Primate. Science 274, 2054-2057 (1996).
51. Moutsopoulos NM, Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG, Moutsopoulos HM. B-Cell epitopes of intracellular autoantigens: Myth and reality. Mol. Med. 6, 141-151 (2000).
52. Halse AK, Marthinussen MC, Wahren Herlenius M, Jonsson R. Isotype distribution of antiRo/SS-A and antiLa/SS-B antibodies in plasma and saliva of patients with Sjogren's syndrome. Scand J. Rheumatol. 29, 13-19 (2000).
53. Zhang JZ, Rivera VM, Tejada-Simon MV et al. T-cell vaccination in multiple sclerosis: results of a preliminary study. J. Neurol. 249, 212-218 (2002).
54. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte cells reactive against myelin basic protein. Nature 292, 60-61 (1981).
55. Zhang J, Medaer R, Stinissen P, Hafler DA, Raus J. MHC restricted clonotypic depletion of human myelin basic protein reactive T-cells by T-cell vaccination. Science 261, 1451-1454 (1993).
56. Zhang J. T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis Expert Rev. Vaccines 1(3), 285-292 (2002).
57. Oksenberg JR, Panzara MA, Begovich AB et al. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362, 68-70 (1993)
58. Hong J, Zang YCQ, Tejada-Simon MV et al. A Common TCR V-D-J Sequence in Vβ13.1 T Cells Recognizing an Immunodominant Peptide of Myelin Basic Protein in Multiple Sclerosis. J. Immunol. 163, 3530-3538 (1999).
59. Noreager BD. Cross-reactive idiotypes: vaccine targets for autoimmune diseases. University of Alabama, Birmingham, AL, USA, PhD dissertation (2002).
60. + regulatory T-cells: their common role in controling autoimmunity, tumor immunity and transplantation tolerance. Immunol. Rev. 182, 18-32 (2002).
61. Tzioufas AG Moutsopoulos HM. Epitopes and complementary epitopes of autoantigens: Candidate probes to study and modulate the autoimmune response. Clin. Exp. Rheum. 20, 289-291 (2002).
62. McAnally JL, Xu L, Villain M, Blalock JE. The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis. Soc. Exp. Biol. Med. 226, 307-311 (2001).
63. Madsen LS, Andersson EC, Jansson L et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23, 343-347 (1999).
64. Zhou EM, Kisil FT. Regulation levels of serum antibodies to ryegrass pollen allergen Lol pIV by an internal image anti-idiotypic monoclonal antibody. Immunology 84, 343-349 (1995).
65. Barker DS, Blalock JE. HyPSCAn. Unpublished computer application.